[Use of proteasome inhibitors in the treatment of patients with multiple myeloma].
Rukavitsyn
O A
OA
D001897:Boronic Acids / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use*; D000069286:Bortezomib; D004305:Dose-Response Relationship, Drug; D006801:Humans; D015850:Interleukin-6 / Q000276:immunology; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000276:immunology; D016328:NF-kappa B / Q000187:drug effects; D011480:Protease Inhibitors / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D011719:Pyrazines / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use*; D012074:Remission Induction; D014409:Tumor Necrosis Factor-alpha / Q000187:drug effects / Q000276:immunology; D042461:Vascular Endothelial Growth Factor A / Q000187:drug effects
D001897:Boronic Acids; D015850:Interleukin-6; D016328:NF-kappa B; D011480:Protease Inhibitors; D011719:Pyrazines; D014409:Tumor Necrosis Factor-alpha; D042461:Vascular Endothelial Growth Factor A; D000069286:Bortezomib